GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 123
- Registration Number
- NCT03434353
- Locations
- 🇰🇷
Catholic University of Korea, Seoul Saint Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT03417778
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd., Grafton, Auckland, New Zealand
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇩🇪APEX GmbH, Munich, Germany
Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
- Conditions
- HIV-1 Infection
- Interventions
- Drug: B/F/TAF
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 86
- Registration Number
- NCT03405935
- Locations
- 🇧🇪
UZ Gent, Ghent, Belgium
🇫🇷Hopital Saint-Andre, Bordeaux, France
🇫🇷C.H.U. de Nantes - Hotel Dieu, Nantes, France
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
- Conditions
- Diffuse Large B-Cell LymphomaMediastinal B-cell Lymphoma
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT03349346
- Locations
- 🇮🇹
Infantile Regina Margherita Hospital, Torino, Italy
🇮🇹Istituto Giannina Gaslini, Genova, Italy
🇫🇷Centre Hospitalier Régional Universitaire de Lille, Lille, France
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT03301506
- Locations
- 🇹🇷
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Topkapı, Turkey
🇬🇧Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Hull Royal Infirmary, Hull, United Kingdom
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
- Conditions
- Lupus Membranous Nephropathy
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT03285711
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT03248479
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
- Conditions
- Pseudomonas Aeruginosa Respiratory Tract Infection/ColonizationCystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 149
- Registration Number
- NCT03219164
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇮🇱Rambam Health Corporation, Haifa, Israel
🇮🇱Lady Davis Carmel Medical Center, Haifa, Israel
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
- Conditions
- Noninfectious Uveitis
- Interventions
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 74
- Registration Number
- NCT03207815
- Locations
- 🇺🇸
Metropolitan Eye Research and Surgery Institute, Palisades Park, New Jersey, United States
🇺🇸Texas Retina Associates - Fort Worth, Fort Worth, Texas, United States
🇺🇸Colorado Retina Associates PC, Golden, Colorado, United States
Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 124
- Registration Number
- NCT03180619
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇨🇦University of Calgary Liver Unit, Calgary, Canada
🇨🇦Centre de Recherche du Centre Hospitalier de l'Universite de Montreal, Montreal, Canada